Methods of using beta-2 adrenergic receptor expression in treatment decisions for cancer therapy
Blood-based biopsies assessing B2AR expression in tumor-associated macrophages provide a non-invasive means to identify breast cancer patients benefiting from beta-blockers, addressing the limitations of traditional tissue biopsies and improving treatment efficacy.
Patent Information
- Application Number
- PCT/US2024/032238
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-06-03
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods for determining the suitability of breast cancer patients for beta-blocker treatment are invasive, painful, and limited in scope, as they rely on tissue biopsies that cannot accurately monitor changes in tumor microenvironments over time.
The use of blood-based biopsies to assay tumor-associated macrophage cells for beta-adrenergic receptor expression, specifically the beta-2 adrenergic receptor (B2AR), to identify patients likely to benefit from beta-blocker therapy, allowing for real-time monitoring and more informed treatment decisions.
This approach enables the identification of patients with high B2AR expression in Cancer Associated Macrophage-Like cells (CAMLs), predicting better outcomes and metastatic potential, thereby guiding the use of beta-blockers in cancer treatment and improving progression-free and overall survival.
Smart Images

Figure US2024032238_05122024_PF_FP_ABST
Abstract
Description
METHODS OF USING BETA-2 ADRENERGIC RECEPTOR EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPYBACKGROUND OF INVENTION
[0001] Use of beta-blockers in breast cancer (BC) patients has been shown to potentially reduce metastasis and recurrence, increase disease-free intervals, and prolong overall survival in patients with metastatic breast cancer
[0001] . Recently, several studies have observed that BC patients prescribed beta-blockers have significant improvements in outcome. A large populationbased study demonstrated that patients prescribed propranolol, a beta-l / beta-2 antagonist, were less likely to have larger tumors and lymph node involvement [2], Furthermore, these patients also had a significantly lower cumulative probability of breast cancer-specific mortality [2], A similar finding was reported from a single-center retrospective study, which showed that patients treated with beta-blocker had a reduction in metastases and reduction in breast cancer-specific mortality [3], Propranolol is a beta-blocker drug which significantly decreased tumor size, nodal spread, and improved overall survival (OS) in BC [2], Lastly, inhibition of beta adrenergic receptors has been shown to reduce incidence of brain metastases in triple-negative BC [4], The role of adrenergic signaling appears to aid in the progression and spread of BC, while targeted inhibition of this receptor appears to improve on patient outcome.
[0002] Beta-2 adrenergic receptor (B2AR) is a member of the 7-transmembrane receptor G protein-coupled receptor (GPCRs), which is activated by stress via catecholamines, such as Epinephrine and Norepinephrine [5], B2AR activation leads to downstream upregulation of cyclic AMP (cAMP) and further activation of protein kinase A (PKA), which can lead to activation of cytokine production, growth factors, cell morphology, and cell death [6], A sign of activation of B2AR is the internalization of the receptor. This process allows for either clearance of ligands for resensitization of the receptor for further signaling or potential lysosomal degradation of the receptor in a downregulation process [7], Imaging of this activation and internalization of B2AR has been shown in various cell lines, including MB-231, by induction using the B2AR agonist isoproterenol [8-10], Notably, the activation of B2AR has also been established in stromal immune cells, like macrophages and other myeloid-derived niche cells, which appear to aid in the secretion of pro-inflammatory and pro-tumorigenic signals within tumors [11-13]. Further, B2AR activation causes migration and differentiation of macrophages attumor sites. These tumor-associated macrophages can block cytotoxic T-cells and inhibit therapeutic treatments from entering the tumor site [14,15], B2AR is highly involved in the tracking of monocytic tumor associated immune cells and whose quantification may provide biological information on the metastatic potential of specific pro-tumorigenic microenvironmental cells
[0013] ,
[0003] As the potential use of beta-blockers may benefit certain BC patients, better methods to distinguish these patients becomes crucial. One potential method may involve measuring the cellular expression of adrenergic receptors such as B2AR on cells disseminating from the tumor site. However, obtaining cancer cells via tumor biopsies for beta-adrenergic receptor surveys has serious drawbacks that include pain and discomfort to patients, the inability to survey more than an isolated area of the tumor, and the potential for protein expression profiles to changes to occur over time in the tumor microenvironment.
[0004] Blood-based biopsies are an improvement on tissue biopsies in that they can provide real time sequential tracking of cells shed by the tumor or that otherwise break-off. Blood samples can be more easily obtained, and obtained more often from a patient. Further, changes in protein expression profiles can be monitored over time.
[0005] The identification of specific cell types that can be obtained from blood-based biopsies will critical to further develop use of this technique for identifying cancer patients that will benefit from treatment with a beta-blocker.
[0006] One such cell type that may be useful in beta-adrenergic receptor surveys is Cancer Associated Macrophage-Like cells (CAMLs), a specific subtype of pro-tumorigenic giant polyploid myeloid cells circulating in the blood of cancer patients, which derive from the tumor stromal microenvironment [16-21], CAMLs express CD45 and CD14 but are distinguished by their polyploid nuclei and their large cell size
[0018] , Recently, CAMLs were shown to present with hematopoietic stem-like and pro-angiogenic phenotypes whose high cell numbers and phagocytic engorgement (i.e., size enlargement) have been associated with poor patient outcomes [20-23], While CAMLs have been theorized to be hematopoietic myeloid immune cells involved in cancer spread, their activation pathway has not been elucidated.BRIEF SUMMARY OF INVENTION
[0007] The present invention relates to peripherally-based biomarkers and the cells that express them for use in screening, monitoring, treating and diagnosis cancer in a subject. The methods defined herein will allow oncologists to make more informed treatment decisions, as well as identify patients likely to show durable responses to anti-cancer therapies.
[0008] In a first embodiment, the invention is drawn to methods of screening a subject having cancer for susceptibility to a beta-blocker, comprising assaying tumor associated macrophage (TAM) cells isolated from a subject having cancer for beta adrenergic receptor (BAR) expression, wherein when BAR expression is detected, the subject is deemed susceptible to a beta-blocker.
[0009] In a second embodiment, the invention is drawn to methods of predicting responsiveness of a subject having cancer to treatment with a beta-blocker, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is predicted to be responsive to treatment with a beta-blocker.
[0010] In a third embodiment, the invention is drawn to methods for selecting a treatment for a subject having cancer, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, administration of a therapeutically effective amount of a beta-blocker to the subject is selected as a treatment for the subject.
[0011] In a fourth embodiment, the invention is drawn to methods for identifying a subject having cancer suitable to receive a beta-blocker treatment, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is identified as a subject suitable to receive a beta-blocker treatment.
[0012] In a fifth embodiment, the invention is drawn to methods of treating a subject having cancer, comprising (a) assaying TAM cells isolated from a subject having cancer for BAR expression, and (b) administering a therapeutically effective amount of a beta-blocker to the subject when BAR expression is detected.
[0013] In a sixth embodiment, the invention is drawn to methods of treating a subject having cancer, comprising administering a therapeutically effective amount of a beta-blocker to a subject having cancer, wherein said beta-blocker is administered after BAR expression is detected in TAM cells isolated from the subject having cancer.
[0014] In a seventh embodiment, the invention is directed to methods of obtaining data for evaluating beta-blocker treatment in a subject having cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from the subject having cancer.
[0015] In an eighth embodiment, the invention is directed to methods of determining a likelihood that a subject having cancer will benefit from beta-blocker treatment, comprising measuring expression of BAR in TAM cells in a sample obtained from the subject having cancer, wherein the subject having cancer is determined as having a relatively high likelihood of benefiting from the beta-blocker treatment when expression of BAR in TAM cells is relatively high, and wherein the subject having cancer is determined as having a relatively low likelihood of benefiting from the beta-blocker treatment when expression of BAR in TAM cells is relatively low.
[0016] In a ninth embodiment, the invention is directed to methods of treating cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from a subject having cancer, and administering a beta-blocker therapy to the subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the betablocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells.
[0017] In a tenth embodiment, the invention is directed to methods of treating cancer, comprising administering a beta-blocker to a subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the beta-blocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells, in a sample obtained from the subject having cancer having been subjected to measurement of expression of BAR in TAM cells to determine the relative expression of BAR.
[0018] In an eleventh embodiment, the invention is directed to methods for predicting overall survival (OS) and / or progression free survival (PFS) of a subject having cancer, comprising determining the presence of TAM cells expressing BAR, wherein the presence of TAM cells expressing BAR predicts lower OS and / or PFS than a subject having the same cancer without the presence of TAM cells expressing BAR.
[0019] In a twelfth embodiment, the invention is directed to methods for predicting presence of metastatic spread and / or metastatic progression in a subject having cancer, comprising determining the presence of TAM cells expressing BAR in a biological sample from a subjecthaving cancer, wherein the presence of TAM cells expressing BAR predicts presence of metastatic spread and / or metastatic progression in the subject.
[0020] In certain of the relevant embodiments and aspects defined above, the beta adrenergic receptor is beta-2 adrenergic receptor (B2AR).
[0021] In certain of the relevant embodiments and aspects defined above, the beta-blocker is one or more of propranolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, esmolol, bButaxamine, ICI-118,551, SR 59230A, and nebivolol. In a specific aspect, the beta-blocker is propranolol.
[0022] In certain of the relevant embodiments and aspects defined above, the TAM cells are Cancer Associated Macrophage-Like cells (CAMLs).
[0023] In certain of the relevant embodiments and aspects defined above, the subject having cancer may be undergoing treatment using one or more of a targeted agent, chemotherapy, or radiation therapy. In certain aspects, the cancer is a lung cancer, breast cancer, prostate cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, head and neck cancer, colorectal cancer, liver cancer, ovarian cancer, neuroblastoma, sarcoma, osteosarcoma, esophageal, brain & ONS, larynx, bronchus, oral cavity and pharynx, stomach, testis, thyroid, uterine cervix, uterine corpus cancer, or a blood cancer. The cancer may be a solid tumor, such as solid tumor of a stage I, stage II, stage III or stage IV cancer. The solid tumor may be carcinoma, sarcoma, neuroblastoma or melanoma. Example of lung cancers include, but are not limited to, non-small cell lung carcinoma (NSCLC).
[0024] In certain of the relevant embodiments and aspects defined above, the subject having cancer is a subject having breast cancer, including a metastatic breast cancer patient.
[0025] In certain of the relevant embodiments and aspects defined above, the methods further comprise administering a therapeutically effective amount of one or more additional anticancer agents to the subject. The additional anti -cancer agents include, but are not limited to, immunotherapeutic agents, chemotherapeutic agents, radiotherapeutic agents, existing cancer drugs, CCR5 antagonists and CXCR4 antagonists. Examples of cancer treatments include, but are not limited to, one or more of antibodies or antagonists that block the activity of CCL3, CCL5 (RANTES), CCL7 or CCL8; Leronlimab (PRO 140); T-VEC, AM-0010, CXCR4 antagonist, TGF-beta kinase inhibitor galunisertib, anti-CSF-lR monoclonal antibody,Abemaciclib, Faslodex, necitumumab, AZD9291 , Cyramza (ramucirumab), TPTV 200, Galunisertib, cancer vaccines, cytokines, cell-based therapies, bi- and multi-specific antibodies, tumor-targeting mAbs, Rituximab, oncolytic viruses, reovirus, Blinatumomab, Sipuleucel-T, T- Vec, IL-2, IFN-a, Trastuzumab, Celuximab, bevacizumab, Tim-3, BTLA, anti-IL-10, GM-CSF, anti-angiogenesis treatment, VEGF blockade, HMGB1, Nrpl, TAM receptor tyrosine kinases, Axl , MerTK, ALT-803, IL-15, Immunosuppressive Ligand Phosphatidyl serine (PS), bavituximab, bevacizumab (anti-VEGF), coblmetinib (MEK inhibitor), vemurafenib (BRAF inhibitor), erlotinib (EGFR), alectinib (ALK inhibitor), bevacizumab (anti-VEGF), pazopanib (tyrosine kinase inhibitor), dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor), durvalumab (anti-PD-Ll), sunitinib (RTK inhibitor), pazopanib (RTK inhibitor), sargramostim, VISTA, TIM-3, LAG-3, PRS-343, CD137 (4-lBB) / HER2 bispecific, USP7, anti-HER2, SEMA4D, CTLA-4, PD-1, PD-L1, and PD-L2. As a non-limiting example, the treatment may be a cancer vaccine and the subject expresses at least one HLA allele.
[0026] In certain of the relevant embodiments and aspects defined above, the assaying for BAR expression may be by one or more of detecting BAR protein expression or detecting BAR mRNA production. BAR expression may be detected, for example, via immunohistochemistry (IHC). IHC may be performed by membrane staining, cytoplasmic staining, or a combination thereof. IHC may be performed using an anti-BAR antibody. BAR expression may also be detected as low (or weak) staining intensity by IHC, moderate staining intensity by IHC, or high (or strong) staining intensity by IHC. BAR expression may also be detected as inducible from low (or weak) staining intensity to high (or strong) staining intensity, or inducible from low (or weak) staining intensity to moderate staining intensity, or inducible from moderate staining intensity to high (or strong) staining intensity. BAR expression may also be detected as any staining of the isolated cells.
[0027] In certain aspects, IHC is performed using immunofluorescence (IF) staining where one or more antibodies with binding specificity for BAR are utilized. Binding of the anti-BAR antibody to BAR may be detected via a fluorescent compound conjugated to the anti-BAR antibody or it may be detected via a fluorophore-conjugated secondary antibody with binding specificity for the anti-BAR antibody.
[0028] In certain of the relevant embodiments and aspects defined above, BAR expression is detected when the level of BAR expression is greater than BAR expression in a population of stromal cells from a subject of the same species that does not have cancer.
[0029] In certain of the relevant embodiments and aspects defined above, TAM cells are isolated from blood obtained from the subject having cancer. In certain aspects, the blood is peripheral blood.
[0030] The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described herein, which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that any conception and specific embodiment disclosed herein may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that any description, figure, example, etc. is provided for the purpose of illustration and description only and is by no means intended to define the limits the invention.BRIEF DESCRIPTION OF DRAWINGS
[0031] Figure 1. Images of Low and High B2AR expressing CAMLs. CAMLs are enlarged cells with a polyploid nucleus (blue), and can be B2AR positive (red), a-d) CAMLs showing low expression of B2AR (box = 60 pm, scale bar = 10 pm) White arrow pointing to potential internalization, e-h) CAMLs showing high expression of B2AR (box = 180 pm, scale bar = 30 pm) White arrow pointing to potential internalization.
[0032] Figure 2. Average B2AR Fluorescence Intensity and Endosome formation from increasing concentrations of Isoproterenol: a) Intensity of B2AR in MDA-MB-231 cell line compared to increases in concentration of isoproterenol. Bars = S.E. b-f) Merged images of MDA-MB-231 cells exposed to isoproterenol at 0, 1 , 2, 5, and 50 pM for 60 minutes, g-k)B2AR images for MDA-MB-231 cells exposed to isoproterenol at 0, 5, 10, 20, and 50 pM for 60 minutes. More doting referred to as endosome formation happens closer to the perinuclear space at increased concentrations of isoproterenol.
[0033] Figure 3. Relationship of B2AR Expression of CAMLs in relation to CAML number & Largest CAML in circulation, a) Whisker Plots of patient’s CAML number based on high / low expression of B2AR. Wilcoxon ranked sum (*p = 0.0093). Red dots = data outliers, b) Whisker Plots of the Largest Diameter CAML from each patient’s sample based on high / low expression of B2AR. Wilcoxon ranked sum (**p = 0.0073).
[0034] Figure 4. Kaplan-Meier graphs of PFS and OS for B2AR expression between High and Low B2AR expressing patients for Total Patient Population, a) PFS of patients with High B2AR CAMLs (mPFS = 3.0 months) versus Low B2AR CAMLs (mPFS = 10.9 months), b) OS of patients with CAMLs High B2AR CAMLs (mOS = 5.5 months ) versus Low B2AR CAMLs (mOS = 13.4 months).
[0035] Figure 5. Expression of various markers on CAMLs. a) Overall cell intensity in MDA-MB-231 cell line compared to increases in concentration of isoproterenol. Bars = S.E.
[0036] Figure 6. Relationship of B2AR Expression on CAMLs and number of CTCs and EMTs in circulation.DETAILED DESCRIPTION OF THE INVENTIONI. Definitions
[0037] As used herein, “a” or “an” may mean one or more. As used herein when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more. Furthermore, unless otherwise required by context, singular terms include pluralities and plural terms include the singular.
[0038] As used herein, “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., + / - 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.II. The Present Invention
[0039] Liquid biopsies provide real-time, sequential tracking of circulating tumor cells (CTCs) found in the peripheral blood and such assays can be used as a substitute to tissue biopsies [32-35], Assessing circulating tumor cells (CTCs) in the peripheral blood has the power to interrogate heterogeneous populations of CTCs, both as a cancer diagnostic as well as a means for monitoring treatment and determining the susceptibility of a tumor in a particular subject to a particular treatment.
[0040] Recently, another circulating cell type associated with cancer has been identified in the peripheral blood of cancer patients. This cancer stromal cell subtype has been termed a Cancer Associated Macrophage-Like cell or CAML [16-21], CAMLs are a type of so-called Tumor Associated Macrophage (TAM) cells. CAMLs have been identified in the blood using a non-affinity microfiltration based method which captures both CTCs and CAMLs, and allows for parallel analysis of these cancer specific circulating cell subtypes [32, 36-46], CAMLs are a recently defined circulating myeloid derived stromal cell, found in all the stages of invasive malignancy and in various solid malignancies (e.g. breast, prostate, non-small cell lung carcinoma (NSCLC), and pancrease) [41, 43, 44, 47], CAMLs are specialized myeloid polyploid cells in the blood in all stages of solid tumors and some blood cancers. They are easy to identify by their large size (greater than 25 pm), polyploid nucleus and morphologies: round, rod shaped, with one tail or two tails about 180 degrees apart. CAMLs typically express CD31, CD14, CD45 and cytokeratin, and can also express EpCAM, CD146, CD11c and tie2 [41, 43, 44, 47], While CAMLs appear to be cancer specific and disseminate from the organ sites of malignancy, it remains unknown if they actually reside at the primary tumor site or if they possess clinical utility.
[0041] The utilization of such circulating cells has not been well studied in liquid biopsies and the present invention is directed to methods of using tumor associated macrophage (TAM) cells, such as CAMLs, in the screening, monitoring, diagnosis and treatment of different cancers, in particular those cancers in which associated TAM cells and CAMLs express a beta adrenergic receptor, such as B2AR, on their surface.Methods of Screen for Susceptibility to Beta-blockers
[0042] As indicated above, the present invention is drawn to methods of screening a subject having cancer for susceptibility to a beta-blocker, comprising assaying tumor associated macrophage (TAM) cells isolated from a subject having cancer for beta adrenergic receptor (BAR) expression, wherein when BAR expression is detected, the subject is deemed susceptible to a beta-blocker.Methods of Predicting Responsiveness to Beta-blockers
[0043] The invention is drawn to methods of predicting responsiveness of a subject having cancer to treatment with a beta-blocker, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is predicted to be responsive to treatment with a beta-blocker.Methods for Selecting Beta-blocker Treatments
[0044] The invention is drawn to methods for selecting a treatment for a subject having cancer, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, administration of a therapeutically effective amount of a beta-blocker to the subject is selected as a treatment for the subject.Assays for Identifying a Subject for Beta-blocker Treatment
[0045] The invention is drawn to methods for identifying a subject having cancer suitable to receive a beta-blocker treatment, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is identified as a subject suitable to receive a beta-blocker treatment.Methods of Treatment Using Beta-blockers
[0046] The invention is drawn to methods of treating a subject having cancer, comprising (a) assaying TAM cells isolated from a subject having cancer for BAR expression, and (b) administering a therapeutically effective amount of a beta-blocker to the subject when BAR expression is detected.
[0047] In a related embodiment, the invention is drawn to methods of treating a subject having cancer, comprising administering a therapeutically effective amount of a beta-blocker to asubject having cancer, wherein said beta-blocker is administered after BAR expression is detected in TAM cells isolated from the subject having cancer.
[0048] In a further embodiment, the invention is directed to methods of treating cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from a subject having cancer, and administering a beta-blocker therapy to the subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the betablocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells.
[0049] In yet a further embodiment, the invention is directed to methods of treating cancer, comprising administering a beta-blocker to a subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the beta-blocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells, in a sample obtained from the subject having cancer having been subjected to measurement of expression of BAR in TAM cells to determine the relative expression of BAR.
[0050] In each of the embodiments and aspects of the invention related to methods of treatment, the methods can be practiced using beta-blockers alone or practiced in conjunction with additional means for treating and inhibiting cancer in a subject. Such additional means will be well known to the skilled artisan and include, but are not limited to means such as anti-cancer chemotherapeutics and radiotherapeutics and surgical removal of a tumor.Methods of Obtaining Data for Evaluating Beta-blocker Treatment
[0051] The invention is directed to methods of obtaining data for evaluating beta-blocker treatment in a subject having cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from the subject having cancer.Methods of Determining Likelihood of Patient to Benefit from Beta-blocker Treatment
[0052] The invention is directed to methods of determining a likelihood that a subject having cancer will benefit from beta-blocker treatment, comprising measuring expression of BAR in TAM cells in a sample obtained from the subject having cancer, wherein the subject having cancer is determined as having a relatively high likelihood of benefiting from the beta-blocker treatment when expression of BAR in TAM cells is relatively high, and wherein the subjecthaving cancer is determined as having a relatively low likelihood of benefiting from the betablocker treatment when expression of BAR in TAM cells is relatively low.Methods of Predicting Overall Survived (OS) and / or Progression Free Survival (PFS)
[0053] In an eleventh embodiment, the invention is directed to methods for predicting overall survival (OS) and / or progression free survival (PFS) of a subject having cancer, comprising determining the presence of TAM cells expressing BAR, wherein the presence of TAM cells expressing BAR predicts lower OS and / or PFS than a subject having the same cancer without the presence of TAM cells expressing BAR.Methods of Predicting Metastatic Spread
[0054] In a twelfth embodiment, the invention is directed to methods for predicting presence of metastatic spread and / or metastatic progression in a subject having cancer, comprising determining the presence of TAM cells expressing BAR in a biological sample from a subject having cancer, wherein the presence of TAM cells expressing BAR predicts presence of metastatic spread and / or metastatic progression in the subject.
[0055] As used herein, the terms “treat”, “treating” and “treatment” have their ordinary and customary meanings, and include one or more of complete or partial clearance of a tumor or cancer from a subject, reducing the size of a tumor in a subject, killing cells of a tumor or cancer in a subject, and ameliorating a symptom of cancer or a tumor in a subject. Treatment means clearing, reducing, killing or ameliorating by about 1% to about 100% versus a subject to which a beta-blocker has not been administered. Preferably, the clearing, reducing, killing or ameliorating is about 100%, about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5% or about 1%. The results of the treatment may be permanent or may continue for a period of days (such as 1, 2, 3, 4, 5, 6 or 7 days), weeks (such as 1, 2, 3 or 4 weeks), months (such as 1, 2, 3, 4, 5, 6 or more months) or years (such as 1, 2, 3, 4, 5, 6 or more years).
[0056] As used herein, the terms “inhibit”, “inhibiting” and “inhibition” have their ordinary and customary meanings, and include one or more of, hindering, impeding, obstructing, deterring or restraining establishment of cancer or a tumor, development of cancer or a tumor, growth ofcancer or a tumor and metastasis. Inhibition means hindering by about 1% to about 100% versus a subject to which a beta-blocker has not been administered. Preferably, the hindering is about 100%, about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5% or about 1%. The methods of inhibition may be practiced in a subject prior to, concurrent with, or after the onset of clinical symptoms of cancer or a tumor. Thus, the subject may have cancer or a tumor, or merely be susceptible to developing cancer or a tumor. The results of the inhibition may be permanent or may continue for a period of days (such as 1, 2, 3, 4, 5, 6 or 7 days), weeks (such as 1, 2, 3 or 4 weeks), months (such as 1, 2, 3, 4, 5, 6 or more months) or years (such as 1, 2, 3, 4, 5, 6 or more years).
[0057] As used herein, the phrases “relatively high likelihood of benefiting from the betablocker treatment” and “relatively low likelihood of benefiting from the beta-blocker treatment” refer to the likelihood of benefitting from treatment versus a subject that does not receive the treatment. A “relatively high likelihood” is 50% or greater likelihood the treatment will be successful, and a “relatively low likelihood” is less than 50% likelihood the treatment will be successful.
[0058] The beta-blockers and pharmaceutical formulations comprising beta-blockers may be administered to a subject using different schedules, depending on the particular aim or goal of the method; the age and size of the subject; and the general health of the subject, to name only a few factors to be considered. In general, the beta-blockers and pharmaceutical formulations may be administered once, or twice, three times, four times, five times, six times or more, over a course of treatment or inhibition. The timing between each dose in a dosing schedule may range between days, weeks, months, or years, an includes administered once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more weeks. The same quantity of beta-blocker may be administered in each dose of the dosing schedule, or the amounts in each dose may vary. The identity of the beta-blocker may also vary or remain the same in each dose in a dosing schedule.
[0059] In each of the methods of the present invention, a “therapeutically effective amount” of a beta-blocker or pharmaceutical formulation comprising a beta-blocker is administered to a subject. The therapeutically effective amount will vary between subjects. However, the therapeutically effective amount is one that is sufficient to achieve the aim or goal of the method,whether inhibiting or treating. As an example, a therapeutically effective amount of a betablocker used in the methods of the invention is typically between about 0.1 pg to about 10,000 pg of beta-blocker per kg of body weight of the subject to which the peptide is administered. A therapeutically effective amount also includes between about 0.5 pg to about 5000 pg, between about 1 pg to about 500 pg, between about 10 pg to about 200 pg, between about 1 pg to about 800 pg, between about 10 pg to about 1000 pg, between about 50 pg to about 5000 pg, between about 50 pg to about 500 pg, between about 100 pg to about 1000 pg, between about 250 pg to about 2500 pg, between about 500 pg to about 2000 pg, between about 10 pg to about 800 pg, between about 10 pg to about 1000 pg, between about 1 pg to about 300 pg, and between about 10 pg to about 300 pg of beta-blocker per kg of body weight of the subject.
[0060] Appropriate doses and dosing schedules can readily be determined by techniques well known to those of ordinary skill in the art without undue experimentation. Such a determination will be based, in part, on the tolerability and efficacy of a particular dose.
[0061] Administration of the beta-blocker or pharmaceutical formulation may be via any of the means commonly known in the art of peptide delivery. Such routes include intravenous, intraperitoneal, intramuscular, subcutaneous and intradermal routes of administration, as well as nasal application, by inhalation, ophthalmically, orally, rectally, vaginally, or by any other mode that results in the beta-blocker or pharmaceutical formulation contacting mucosal tissues.
[0062] The pharmaceutical formulations of the invention comprise one or more beta-blockers and a pharmaceutically acceptable carrier. Suitable examples of carriers are well known to those skilled in the art and include water, water-for-inj ection, saline, buffered saline, dextrose, glycerol, ethanol, propylene glycol, polysorbate 80 (Tween-80™), poly(ethylene)glycol 300 and 400 (PEG 300 and 400), PEGylated castor oil (e.g. Cremophor EL), poloxamer 407 and 188, hydrophilic and hydrophobic carriers, and combinations thereof. Hydrophobic carriers include, for example, fat emulsions, lipids, PEGylated phospholipids, polymer matrices, biocompatible polymers, lipospheres, vesicles, particles, and liposomes. The terms specifically exclude cell culture medium. The formulations may further comprise stabilizing agents, buffers, antioxidants and preservatives, tonicity agents, bulking agents, emulsifiers, suspending or viscosity agents, inert diluents, fillers, and combinations thereof.
[0063] A kit comprising the necessary components for practicing the methods disclosed herein is also within the purview of the present invention. The kit comprises one or more beta-blockers and instructions for use. In some aspects, the one or more beta-blockers are in a pharmaceutical formulation comprising the beta-blockers and a pharmaceutically acceptable carrier.Beta-blockers
[0064] As used herein, the term “beta-blocker” refers to a compound, such as a drug (including an antibody), that inhibits or blocks the activity and / or expression of beta adrenergic receptors, such as beta-2 adrenergic receptors (B2AR). Beta-blockers are also often referred to as “beta-adrenergic blocking agents”. Beta adrenergic receptors are expressed by cells, including cells of the immune system, such as stromal immune cells, like macrophages, and some types of cancer cells. B2AR activation leads to downstream upregulation of cyclic AMP (cAMP) and further activation of protein kinase A (PKA), which can lead to activation of cytokine production, growth factors, cell morphology, and cell death [6], A sign of activation of B2AR is the internalization of the receptor. This process allows for either clearance of ligands for resensitization of the receptor for further signaling or potential lysosomal degradation of the receptor in a downregulation process [7], Imaging of this activation and internalization of B2AR has been shown in various cell lines, including MB-231, by induction using the B2AR agonist isoproterenol [8-10], Notably, the activation of B2AR has also been established in stromal immune cells, like macrophages and other myeloid-derived niche cells, which appear to aid in the secretion of pro-inflammatory and pro-tumorigenic signals within tumors [11-13], Further, the B2AR activation causes migration and differentiation of macrophages at tumor sites. These tumor associated macrophages can block cytotoxic T-cells and inhibit therapeutic treatments from entering the tumor site [14,15], B2AR is highly involved in the tracking of monocytic tumor associated immune cells and whose quantification may provide biological information on the metastatic potential of specific pro-tumorigenic microenvironmental cells
[0013] ,
[0065] The beta-blockers of present invention included, but are not limited to, BAR and B2AR antagonists, such as inhibitors of binding between BAR and its cognate ligands and between B2AR and its cognate ligand.
[0066] The beta-blockers of present invention included, but are not limited to, antibodies, such as monoclonal antibodies. In particular aspects, the beta-blockers is a human antibody, a humanized antibody, or a chimeric antibody. The beta-blockers also include fragments ofantibodies that retain their inhibitory activity. Such antibody fragments include, but are not limited to, Fab fragments, F(ab')2 fragments, and single chain Fv (scFv).
[0067] Examples of specific beta-blockers include, but are not limited to, propranolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, esmolol, bButaxamine, ICI-118,551, SR 59230A, and nebivolol.Anti-cancer Agents
[0068] In the embodiments and aspects of the invention directed to the treatment of cancer, the methods may include the administration of a therapeutically effective amount of one or more anti-cancer agents to the subject in addition to the beta-blocker.
[0069] The anti-cancer agents are only limited in that they be compatible with the betablockers that are also administered to the subject.
[0070] Additional anti-cancer agents include, but are not limited to, immunotherapeutic agents, chemotherapeutic agents, radiotherapeutic agents, existing cancer drugs, CCR5 antagonists and CXCR4 antagonists. Examples of cancer treatments include, but are not limited to, one or more of antibodies or antagonists that block the activity of CCL3, CCL5 (RANTES), CCL7 or CCL8; Leronlimab (PRO 140); T-VEC, AM-0010, CXCR4 antagonist, TGF-beta kinase inhibitor galunisertib, anti -CSF-1R monoclonal antibody, Abemaciclib, Faslodex, necitumumab, AZD9291, Cyramza (ramucirumab), TPIV 200, Galunisertib, cancer vaccines, cytokines, cell-based therapies, bi- and multi -specific antibodies, tumor-targeting mAbs, Rituximab, oncolytic viruses, reovirus, Blinatumomab, Sipuleucel-T, T-Vec, IL-2, IFN-a, Trastuzumab, Celuximab, bevacizumab, Tim-3, BTLA, anti-IL-10, GM-CSF, anti-angiogenesis treatment, VEGF blockade, HMGB1, Nrpl, TAM receptor tyrosine kinases, Axl , MerTK, ALT- 803, IL- 15, Immunosuppressive Ligand Phosphatidylserine (PS), bavituximab, bevacizumab (anti-VEGF), coblmetinib (MEK inhibitor), vemurafenib (BRAF inhibitor), erlotinib (EGFR), alectinib (ALK inhibitor), bevacizumab (anti-VEGF), pazopanib (tyrosine kinase inhibitor), dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor), durvalumab (anti-PD-Ll), sunitinib (RTK inhibitor), pazopanib (RTK inhibitor), sargramostim, VISTA, TIM-3, LAG-3, PRS-343, CD137 (4-lBB) / HER2 bispecific, USP7, anti-HER2, SEMA4D, CTLA-4, PD-1, PD-L1, andPD-L2. As a non-limiting example, the treatment may be a cancer vaccine and the subject expresses at least one HLA allele.Means for Assaying Beta Adrenergic Receptor Expression
[0071] As will be apparent, the methods of the present invention are based on assaying, i.e. detecting and / or measuring beta adrenergic receptor (BAR) expression in a cell. In one aspect of the invention, each of the methods defined herein can be used by simply determining whether a selected cell expresses beta adrenergic receptor. Thus, these methods can be performed without the need to quantify the amount of beta adrenergic receptor expression in a cell. However, and in another aspect of the invention, each of the methods defined herein can be used by determining the relative or specific amount of beta adrenergic receptor expressed by a cell. The relative amount may be determined, for example, by determining whether a cell expresses more or less beta adrenergic receptor than another cell or pre-determined standard. The specific amount may be determined, for example, by quantifying the level of beta adrenergic receptor expression in a cell. The beta adrenergic receptor may be, for example, beta-2 adrenergic receptor (B2AR).
[0072] Beta adrenergic receptor expression may be assayed by one or more of detecting / measuring beta adrenergic receptor protein expression and detecting / measuring beta adrenergic receptor mRNA production. Beta adrenergic receptor protein expression may be detected / measured, for example, via immunohistochemistry (IHC). IHC may be performed by membrane staining, cytoplasmic staining, or a combination thereof. IHC may be performed using an anti-beta adrenergic receptor antibody. Beta adrenergic receptor expression may be detected / measured as a weak staining intensity, moderate staining intensity, or strong staining intensity. Beta adrenergic receptor expression may also be detected as a low staining intensity, moderate staining intensity, or high staining intensity. Beta adrenergic receptor expression may also be detected as inducible from low staining intensity to high staining intensity, or inducible from low staining intensity to moderate staining intensity, or inducible from moderate staining intensity to high staining intensity. Beta adrenergic receptor expression may also be detected / measured as any staining of the isolated cells, for example, an amount of staining above background.
[0073] In certain aspects, IHC is performed using immunofluorescence (IF) staining. One or more antibodies with binding specificity for beta adrenergic receptor may be utilized to detectbeta adrenergic receptor protein expression. Binding of the anti -beta adrenergic receptor antibody to beta adrenergic receptor may be detected via a fluorescent compound conjugated to the anti-beta adrenergic receptor antibody or it may be detected via a fluorophore-conjugated secondary antibody with binding specificity for the anti-beta adrenergic receptor antibody.
[0074] In certain of the relevant embodiments and aspects defined above, beta adrenergic receptor expression is determined to be detected when the level of beta adrenergic receptor expression is greater than beta adrenergic receptor expression is a population of stromal cells from a subject of the same species that does not have cancer.Source of Cells
[0075] The cells used in the methods of the present invention include tumor associated macrophage (TAM) cells, such as CAMLs.
[0076] The source of the biological sample from which the cells are obtained is one or more of, blood (such as peripheral blood), lymph node, bone marrow, cerebral spinal fluid, and urine. When the biological sample is blood, the blood may be antecubital-vein blood, inferior-venacava blood femoral vein blood, portal vein blood, or jugular-vein blood, for example. The sample may be a fresh sample or a cryo-preserved sample that is thawed.
[0077] In each of the methods of the invention, it will be apparent that the amount of the biological sample in which the circulating cells (e.g., CAMLs) are assayed can vary. However, the biological sample should generally be at least about 2.5 mL. The amount of biological sample may also be at least about 3, 4, 5, 6, 7, 7.5, 8, 9, 10, 11, 12, 12.5, 13, 14, 15, 16, 17, 17.5, 18, 19, 20, 21, 22, 22.5, 23, 24, 25, 26, 27, 27.5, 28, 29, or 30 mL, or more. The amount of biological sample may also be between about 2.5 and 20 mL, between about 5 and 15 mL, or between about 5 and 10 mL. In one aspect of the invention, the biological sample is about 7.5 mL.
[0078] In each of the embodiments and aspects of the invention, the circulating cells (e.g., CAMLs) are isolated from the biological samples for the determining steps using one or more means selected from size exclusion methodology, immunocapture, red blood cell lysis, white blood cell depletion, a high-molecular weight polysaccharide such as FICOLL®, electrophoresis, dielectrophoresis, flow cytometry, magnetic levitation, and various microfluidic chips, slits, channels, hydrodynamic size-based sorting, grouping, trapping, concentrating large cells,eliminating small cells, or a combination thereof. In a particular aspect, the size exclusion methodology comprises use of a microfilter.
[0079] In one aspect of the invention, circulating cells are isolated from the biological samples using size exclusion methodology that comprises using a microfilter. Suitable microfilters can have a variety of pore sizes and shapes. The microfilter may have a pore size ranging from about 5 microns to about 20 microns. In certain aspects of the invention, the pore size is between about 5 and 10 microns; in other aspects, the pore size is between about 7 and 8 microns. The larger pore sizes will eliminate most of the WBC contamination on the filter. The pores of the microfilter may have any shape, with acceptable shapes including round, race-track shape, oval, slit, square, rectangular and / or other shapes. The microfilter may have precision pore geometry, uniform pore distribution, more than one pore geometry, and / or non-uniform distribution. The microfilter may be single layer, or multi-layers with different shapes on different layers.
[0080] In another aspect of the invention, circulating cells are isolated from the biological samples using a microfluidic chip via physical size-based sorting, slits, channels, hydrodynamic size-based sorting, grouping, trapping, immunocapture, concentrating large cells, or eliminating small cells based on size. The circulating cell capture efficiency can vary depending on the collection method. The size of a circulating cell that can be captured on different platforms can also vary depending, for example, on the identity of the cell. Collection of circulating cells using CELLSIEVE™ microfilters provides 100% capture efficiency and high quality cells.
[0081] In another aspect of the invention, when the biological sample is peripheral blood or blood, the sample may be collected from a subject using a blood collection tube. CELLSAVE™ blood collection tubes (Menarini Silicon Biosystems Inc., San Diego, CA), for example, provide stable cell morphology and size.
[0082] In another aspect of the invention, circulating cells can be captured and analyzed without specifically identifying the cells as CAML cells per se. Instead, one may simply identify the cells based on size of the cytoplasm and nucleus. Examples for doing so are techniques using color metric stains, such as H&E stains, or merely looking at CK (+) cells.
[0083] In a further aspect of the invention, circulating cells are isolated from the biological samples using a CELLSIEVE™ microfilter low-pressure microfiltration assay.Subjects
[0084] The subjects mentioned in the methods of the present invention will be a human, a non-human primate, bird, horse, cow, goat, sheep, a companion animal, such as a dog, cat or rodent, or other mammal.
[0085] The subject having cancer may be a subject undergoing treatment for the cancer. Such treatments include, but are not limited to targeted agents, chemotherapy, and radiation therapy. The cancer may be one or more of lung cancer, breast cancer, prostate cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, head and neck cancer, colorectal cancer, liver cancer, ovarian cancer, neuroblastoma, sarcoma, osteosarcoma, esophageal, brain & ONS, larynx, bronchus, oral cavity and pharynx, stomach, testis, thyroid, uterine cervix, or uterine corpus cancer, or a blood cancer. The cancer may be a solid tumor, such as solid tumor of a stage I, stage II, stage III or stage IV cancer. The solid tumor may be, but is not limited to, carcinoma, sarcoma, neuroblastoma or melanoma. Example of lung cancers include, but are not limited to, non-small cell lung carcinoma (NSCLC).Companion Diagnostics
[0086] The information obtained using the methods of the invention can be used as a companion or complementary diagnostic. A companion or complementary diagnostic is a diagnostic test that can be used in combination with a therapeutic drug for a selected disease or condition. The companion diagnostic determines the suitability of the drug for treatment of the disease or condition in a particular patient, i.e. the companion diagnostic can help to predict whether the subject will be a responder or non-responder to the effects of the drug on the disease or condition in the subject. Thus, the companion diagnostic provides information that is used in treatment decisions and that is essential for the safe and effective use of a corresponding drug or biological product.III. ExamplesMaterials and MethodsCell Culture and Bioassay
[0087] MB-MDA 231 cell line was purchased from the ATCC and cultured to full confluence in accordance with ATCC guidelines in Leibovitz (L- 15) Media with the addition of10% FBS in O2 incubation. Cells were trypsinized and plated on two 8 well plates at 1x10?cells / well (Nunc). After an overnight attachment period, media was aspirated, cells were treated with a) media alone, B) media+ 2 pM of isoproterenol for 15 minutes, C) media+ 2 pM of isoproterenol for 30 minutes, D) media+ 2 pM of isoproterenol for 60 minutes. The second plate was then treated as follows: A) media alone as untreated control, B) media+ 1 pM isoproterenol for 1 hour, C) media+ 2 pM isoproterenol for 1 hour, D) media+ 5 pM isoproterenol for 1 hour, E) media+ 50 pM isoproterenol for 1 hour. (All experiments were run in replicates of four following above protocol). At each experimental endpoint above, wells were aspirated, and 250 pL of 1% paraformaldehyde in PBS was added to each well for 15 minutes. After 15 minutes of exposure, the wells were washed with IX PBS and replaced with 250 pL of 1% Tween-20 for an additional 15 minutes, followed by 250 pL of blocking in lXPBS+2% BSA. Wells were washed with 1XPBS and stained according to the manufacturer’s protocol for immunofluorescence with 1 :200 dilution of B2AR antibody (Cell Signaling clone D6H2)) for 1 hour. Wells were then washed with 5mL 1XPBS+0. l%Tween-20 and mounted using Flouromount-G with DAPI (Southern Biotech). Cells (n=10 cells) were measured for each well for all four replicates of the experiment. Average fluorescence intensity and standard deviation measurements were recorded for both time-gated and dose escalation experiments.Cohort recruitment
[0088] This single blind prospective pilot study was initiated to analyze the expression of B2AR on CAMLs found in the peripheral blood of late-stage breast cancer (BC) patients. Blood samples were procured from 31 late-stage (stage III or IV) BC patients through collaboration efforts with Northwestern University, the Mayo Clinic Cancer Center, University of Maryland, and Thomas Jefferson University, in accordance with the local institutional review board (IRB) approval and with the patient’s informed written consent. BC patients were recruited from November 2015 thru October 2020. Inclusion criteria for this study included patients with late- stage BC above the age of 18 (minors were not included in this study). For enumeration analysis, 7.5 mL blood samples were obtained from BC patients, collected using CellSave Preservation Tubes (Menarini-Silicon Biosystems), anonymized, shipped and analyzed within 96 hours for CAML enumeration and B2AR expression at the Creatv MicroTech facility. Patients’ medical status was monitored for 24 months after treatment induction with clinical variables, includingage, gender, resectability, pathological staging when available, neoadjuvant and adjuvant therapeutics all being evaluated (Table 1).Table 1. Demographic table of patients used in study.Total Number (n=31)Age Median (Range) 58.5 (34-84)RaceCaucasian 18 (58.1%)African American 3 (9.7%)Asian American 1 (3.2%)Hispanic 1 (3.2%)Othcr / Unknown 7 (22.6%)HistologyInvasive Ductal Carcinoma 18 (58.1%)Invasive Lobular Carcinoma 2 (6.5%)Inflammatory Breast Cancer 2 (6.5%)Unknown Histology 9 (29.0%)Grade . II . 5 (16.1%) .IH 12 (38.7%)Unknown Grade 14 (45.2%)Pathological StageAnalysis of Filters
[0089] Patient samples were filtered using Cell Sieve™ microfilter, as previously described. Samples were prefixed for 15 min prior filtration, followed by CellSieve™ microfiltration using a vacuum at a pre-calibrated pressure. Blood samples were further treated with post-fixation and permeabilization buffer, and stained using 1:200 B2AR monoclonal antibody stain (Cell Signaling). Briefly, CTCs, EMTs, and CAMLs were evaluated based on morphological features and expression of other biomarkers such as cytokeratin and CD45. CAML expression profiles for markers such as cytokeratin, CD45, CD14, PDL-1, and B2AR were included. For standardization, background intensity was subtracted from the cellular intensity. Filter analysis was done using an Olympus BX51 WI fluorescent microscope with imaging using a Carl ZeissAxioCam monochrome camera for CAML enumeration (Fig. 1). Zen201 1 Blue program was used for the processing of the images. Cell size and intensity measurements tools were analyzed using precalibrated Zen2011 Blue software.Statistical Analysis
[0090] Univariate analysis of B2AR expression on CAMLs was done using Cox proportional hazard regression at a statistical threshold of p<0.05, using MATLAB R2020. Comparison between CAML number and size in high and low B2AR expressing groups was done using Wilcoxon ranked sum analysis (Fig. 1). Progression-free survival (PFS) and overall survival (OS) Kaplan-Meier estimations were done using the time to progression and mortality, defined as the time interval between first induction of treatment to the occurrence of an event, by standard RECIST criteria using PET / CT scans or death, within a 2-year endpoint.Results
[0091] MDA-MB-231 cell lines were used to optimize and model the B2AR expression and observe its potential activation and internalization in this polynucleated cell line model. The cell lines were treated with varying concentrations of isoproterenol for 60 minutes to induce activation of the adrenergic pathway (Fig. 2). Average B2AR expressions were measured without the addition of isoproterenol or with an introduction using concentrations of 1 pM, 2 pM, 5 pM, 50 pM over 60 min. It was observed that prior to treatment with isoproterenol, B2AR expression in MDA-MB-231 mainly resided on the cell surface when grown in standard L-15 media with an average fluorescence intensity of 314 (Fig. 2 a, b & g). Once exposed to a 1 pM isoproterenol for 1 hr, average intensity non-significantly rose to 465 with the observed presence of dotting, theorized to be an example of internalization of the B2AR marker (T-test, p=0.175) (Fig. 2 a, c, & h)
[0012] .This trend continued with increasing concentration to 2 pM, showing both internalization events and increased average fluorescence intensity of 543 (T-test, p=0.496) (Fig. 2 a, d, & i). Average intensity reached a peak with the introduction of 5 pM, with an average intensity of 858 and a significantly increasing observable internalization events (T-test, p=0.027) (Fig. 2 a, e, & j). Somewhat paradoxically, when isoproterenol is introduced at a concentration of 50 pM, there was a non-significant decline in average intensity to 591 (T-test, p=0.079) (Fig.2 a, f, & k). This may be due to an oversaturation of the B2AR receptor, as most of the B2AR appears to have been internalized into the cell, as found in previous literature [12, 24],
[0092] A dose-escalation bioassay run in conjunction evaluated the effects of isoproterenol at various exposure times of the optimized 2 pM concentration at 0 min, 15 min, 30 min, & 60 min exposure times. In this gated experiment, the average intensity quickly peaked within 15 minutes of exposure, with an average intensity of 640 (Fig. 5 a, d, & e). The intensity appeared to plateau between 15 min and 30 min exposure times, as the average intensity was once again -640 (Fig. 5 a, f, & g). After 60 minutes of exposure, the average intensity dropped -15% to 548, suggesting the bioassay reached saturation (Fig. 5 a, h, & i). These results suggest that prolonged B2AR signaling can result in upregulation of B2AR on a cell’s surface and may result in increased internalization of the receptor.
[0093] A total of 42 blood samples were acquired from 31 individual patients, with 8 patients having serial follow-up blood samples for analysis (Table 1). Among 31 patients, 30 patients had stage IV disease, and 1 patient had stage IIIB. The distribution of histology was 58.1% (n=l 8 / 31) invasive ductal carcinoma, 6.5% (n=2 / 31) invasive lobular carcinoma, 6.5% (n=2 / 31) inflammatory breast cancer, and 29.0% (n=9 / 31) having an unknown histology. The mean age was 57 years old (range 35-84 years). At the end of the 2-year observation period, (n=24 / 31) progressed with (n=5 / 31) patients censored and (n=2 / 31) patients lacking survival information. Further, (n=l 1 / 31) patients experienced death within 2 years, with an additional (n=18 / 31) patient being censored.
[0094] Cll lines were used to model B2AR expression profiles for cell surface and internalization of the receptor. However, it was determined that using a threshold of 65 was optimal in stratifying the patients in terms of high / low expression. 14 out of 42 samples had low B2AR expression, and 28 out of 42 samples had high B2AR expression. The median number of CAMLs was 7 CAMLs / sample in all blood samples, and the median CAML size was 120 microns. Further, it was determined that samples with high B2AR expression on CAMLs had significantly higher number of CAMLs per sample versus low B2AR expression on CAMLs had fewer number of CAMLs (19 vs. 4 CAMLs / samples, p=0.0093; Fig. 3 a). Moreover, patients with high B2AR expression in CAMLs had significantly larger CAMLs versus low B2AR expression in CAMLs had smaller CAMLs (151 pm vs. 62 pm, p=0.0073; Fig. 3 b). However, B2AR measurements on CTCs were not possible as only 13 out of 42 samples had CTCs incirculation, and only 2 samples had CTCs available for B2AR analysis. Further, higher expression of B2AR on CAMLs did not correlate to increased numbers of CTCs (p=0.1565) or EMTs (p=0.5527) found in circulation (Fig. 6).
[0095] Once relationships between B2AR expression on CAMLs and their number and size were identified, the patient’s progression free survival (PFS) and overall survival (OS) was monitored over 2 years. Overall, patients with low B2AR had an increased median PFS (mPFS) of 10.9 months and median OS (mOS) of 13.4 months. In contrast, in patients with high B2AR expression, the mPFS was 3.0 months and the mOS was 5.5 months. In addition, logrank analysis of 24 months PFS found that high B2AR expressing patients progressed at significantly faster rates (HR=3.5, 95% CI=1.5-8.7, p=0.0097) (Fig. 4 a) and had significantly faster rates of mortality (HR=5.0, 95% 01.4-17.2, p=0.0265) (Fig. 4 b).
[0096] In this study, the expression of B2AR was optimized and quantified on the model breast cancer cell line MDA-MB-231 for activation, expression, and internalization of a well- established sympathetic nervous system hormone / neurotransmitter-based receptor. To accomplish this, two separate bioassays were run in conjunction to test 1) the dose-escalation effects of isoproterenol and 2) the effects of exposure time to the chemical on the expression of the adrenergic receptor. The cell line models demonstrated the two types of B2AR expression profiles, upregulation in expression in response to B2AR stimulation and internalization seen in the form of dotting. These various expression profiles acted as an observable model for analyzing and quantifying increased B2AR stimulation in patients’ circulating cells. In the 42 samples from the 31 BC patients, different expression profiles and similar dotting were believed to be internalization found in patients' CAML samples (Fig. 1). This appears to suggest adrenergic pathway signaling within CAMLs and may support the hypothesis that CAMLs originate from stemmy niches in the body.
[0097] The initial cell line experiments were based on literature involving B2AR activation and the use of agonists like isoproterenol [25, 26], In the presence of isoproterenol, many MDA- MB-231 cells formed pools of B2AR receptors (Fig. 2 c-f, h-k). These pools of B2AR formed quickly after exposure to isoproterenol, with collections appearing 15 minutes post-exposure to the agonist (Fig. 5 d & e), which corresponds to prior literature
[0025] , An interesting observation was made in the time-sensitive bioassay (Fig. 5). Between 15 and 30 minutes, the intensity of the signal plateaued (Fig. 5 a), indicating that the upregulation of B2AR occurred early post-exposure to the agonist and remained at similar intensities after this initial rise in expression. In addition, after 60 minutes of exposure to isoproterenol, the B2AR appeared to decline in expression intensity. This may be due to the competitive inhibition resulting from receptor internalization. As receptors become ligand-bound, the cell internalizes the receptor to resensitize it for future signaling. Theoretically, as more B2AR pools together and is internalized, a process that leads to resensitizing and recycling the receptor back to the cell surface, the cell surface intensity of B2AR would logically decline during this process. Also of interest is the effect of dose escalation on the B2AR receptor in response to increasing isoproterenol concentrations. As greater concentrations of isoproterenol are used, the average intensity of B2AR rises greatly in expression (Fig. 2 a). This rise in expression persists until adding a 50 pM concentration of the beta-adrenergic agonist. This may be due to the over saturation of the agonist, causing much greater internalization into the MDA-MB-231 cells, resulting in lower cell surface B2AR intensity. Although not quantifiable in this experiment design, greater pooling and internalization events were observable in the 50 pM cell lines (Fig. 2 f & k). Similar to the exposure time assay (Fig. 5 h-i), it was hypothesized that as more B2AR is internalized, less surface signal and lower expressions are measured.
[0098] Within patient samples, increased B2AR expression on CAMLs appeared to show a significant positive correlation to increased numbers of CAMLs found in circulation (Fig. 3 a), as well as a significant positive correlation to larger CAMLs found in circulation (Fig. 3 b). Further, the higher expression of B2AR appeared to be predictive of both PFS (p=0.0097) and OS (p=0.0265) (Fig. 4). These results suggest a relationship of adrenergic signaling in BC to progression and aggressiveness of disease as they relate to these circulating cell populations.
[0099] Increased tumor associated macrophage (TAMs) invasion in breast cancer can have immunosuppressive and pro-turn ori enic effects
[0013] , As the proportion of stromal tissue occupied by TAMs increases, less cytotoxic T-cells and treatments are able to reach the innermost tumor cells; therefore, it has been suggested that decreasing monocyte / macrophage migration to neoplastic sites is vital for advancing treatment. As increased B2AR signaling has been suggested to have activation and migratory effect in stromal macrophages within tumor microenvironments, it becomes important to better understand the underlying biologic effect of BC [6, 11, 15], CAMLs have been shown to be circulating cells of myeloid stromal origin as they stain positive for markers CD14 & CD45 and emanate from primary tumors [17, 27],CAMLs are a defined subgroup of TAMs and may function similarly by preventing the entry of other immune cells and cytotoxic therapies. Therefore, it can be hypothesized that patients who have greater expression of B2AR on CAMLs may also have greater increased activation and intravasation. Previous literature has described that increased adrenergic signaling in cancer can increase cancer growth [6, 10, 28], Further, increases in tumor associated macrophage activation has been suggested to increase the migration of these myeloid cells [14, 29], As such, it stands to reason that the increased B2AR signaling and activation in CAMLs maybe related to the increased number in circulation. The presence of high expression of B2AR on CAMLs and the association with poorer clinical outcomes suggests a relationship between CAMLs, beta- adrenergic signaling, and patient progression. As the usage of beta-adrenergic antagonists decreases macrophage migration in tumor sites, it might be possible that B2AR expression on CAML migration may also be affected by these antagonists
[0015] , If these patterns hold, this could explain a potential biological mechanism of B2AR and migration of myeloid cells. If CAMLs are being activated by epinephrine / norepinephrine which is causing increased migration to and from tumor sites, this might offer another potential site for therapeutic intervention as an immune-modulating response.
[0100] In this study, high B2AR expression on CAMLs was significantly associated with shorter PFS and OS. B2AR has long been a theoretical target in the treatment of BC [6,30], and recent studies have shown the therapeutic effect of beta-adrenergic antagonists in decreased signaling, inhibition of pro-metastatic cellular & molecular pathways, and lowering disease recurrence
[0031] ,
[0101] While the invention has been described with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various modifications may be made without departing from the spirit and scope of the invention. The scope of the appended claims is not to be limited to the specific embodiments described.REFERENCES
[0102] All patents and publications mentioned in this specification are indicative of the level of skill of those skilled in the art to which the invention pertains. Each cited patent andpublication is incorporated herein by reference in its entirety. All of the following references have been cited in this application:1. Powe, D. G. et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1, 628-638, doi : 10.18632 / oncotarget.101009 (2010).2. Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29, 2635-2644, doi: 10.1200 / JC0.2010.33.5422 (2011).3. Melhem-Bertrandt, A. et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29, 2645-2652, doi: 10.1200 / JC0.2010.33.4441 (2011).4. Choy, C. et al. Inhibition of beta2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative beta-blockade. Oncol Rep 35, 3135-3142, doi: 10.3892 / or.2016.4710 (2016).5. Johnson, M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117, 18-24; quiz 25, doi: 10.1016 / j jaci.2005.11.012 (2006).6. Cole, S. W. & Sood, A. K. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18, 1201-1206, doi: 10.1158 / 1078-0432.CCR-l l-0641 (2012).7. Kurose, H. P2-Adrenergic receptors: Structure, regulation and signaling by partial and full agonists. Allergology International 53, 321-330 (2004).8. Gargiulo, L. et al. Differential beta(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget 5, 10058-10069, doi: 10.18632 / oncotarget.2460 (2014).9. Gargiulo, L. et al. A Novel Effect of beta- Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer. J Mammary Gland Biol Neoplasia 22, 43-57, doi: 10.1007 / sl0911-017-9371-1 (2017).10. Perez Pinero, C., Bruzzone, A., Sarappa, M. G., Castillo, L. F. & Luthy, I. A. Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 166, 721-736, doi: 10.1111 / j .1476- 5381.2011.01791.x (2012).Galvan, D. L. & Danesh, F. R. beta2-adrenergic receptors in inflammation and vascular complications of diabetes. Kidney Int 92, 14-16, doi:10.1016 / j.kint.2017.03.024 (2017). Shumay, E., Gavi, S., Wang, H. Y. & Malbon, C. C. Trafficking of beta2-adrenergic receptors: insulin and beta-agonists regulate internalization by distinct cytoskeletal pathways. J Cell Sci 117, 593-600, doi: 10.1242 / jcs.00890 (2004). Tariq, M. et al. Macrophage Polarization: Anti-Cancer Strategies to Target Tumor- Associated Macrophage in Breast Cancer. J Cell Biochem 118, 2484-2501, doi: 10.1002 / jcb.25895 (2017). Campbell, J. P. et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10, el001363, doi: 10.1371 / journal.pbio.1001363 (2012). Murugan, S., Rousseau, B. & Sarkar, D. K. Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer. Cancers (Basel) 13, doi : 10.3390 / cancers 13194858 (2021 ) . Adams, D. L. et al. Circulating Cancer- Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev 25, 1037-1042, doi: 10.1158 / 1055-9965.EPI-15-1221 (2016). Adams, D. L., Alpaugh, R. K., Tsai, S., Tang, C. M. & Stefansson, S. Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep 6, 33488, doi: 10.1038 / srep33488 (2016). Adams, D. L. et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111, 3514-3519, doi: 10.1073 / pnas.1320198111 (2014). Cristofanilli, M. Liquid Biopsies in Solid Tumors-Chapter 5. (Springer International Publishing, 2018). Tang, C. M. & Adams, D. L. Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients. Biomedicines 10, doi: 10.3390 / biomedicinesl0030587 (2022).Tang, C M. et al. Blood-based biopsies-clinical utility beyond circulating tumor cells. Cytometry A 93, 1246-1250, doi: 10.1002 / cyto.a.23573 (2018). Gardner, K. P., Aldakkak, M., Tang, C. M., Tsai, S. & Adams, D. L. Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes. NPJ Precis Oncol 5, 25, doi: 10.1038 / s41698-021-00161-8 (2021). Gironda, D. J. et al. Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. J Transl Med 18, 413, doi: 10.1186 / sl2967-020- 02563-x (2020). Morrison, K. J. et al. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. Mol Pharmacol 50, 692-699 (1996). von Zastrow, M. & Kobilka, B. K. Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J Biol Chem 267, 3530-3538 (1992). Wang, L. P. et al. Norepinephrine attenuates CXCR4 expression and the corresponding invasion of MDA-MB-231 breast cancer cells via beta2-adrenergic receptors. Eur Rev Med Pharmacol Sci 19, 1170-1181 (2015). Adams, D. L. et al. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin Cancer Res 23, 5948-5958, doi: 10.1158 / 1078-0432.CCR-17-0802 (2017). Pon, C. K., Lane, J. R., Sloan, E. K. & Halls, M. L. The beta2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. FASEB J 30, 1144-1154, doi: 10.1096 / fj .15-277798 (2016). Raghavakaimal, A. et al. CCR5 Activation and Endocytosis in Circulating Tumor- Derived Cells Isolated from the Blood of Breast Cancer Patients Provide Information about Clinical Outcome. Breast Cancer Research 24, doi: 10.1186 / sl3058-022-01528-w (2022). Perez-Sayans, M. et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 19, 45-54, doi:10.3727 / 096504010xl2828372551867 (2010).Shaashua, L. et al. Perioperative COX-2 and beta- Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Clin Cancer Res 23, 4651-4661, doi: 10.1158 / 1078-0432.CCR-17-0152 (2017). Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, et al. The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Advances. 2014;4:4334-42. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clinical chemistry. 2011;57: 1242-55. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature reviews Cancer. 2008;8:329-40. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer letters. 2007;253: 180-204. Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, et al. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch((R)) CTC test. Cytometry Part A : the journal of the International Society for Analytical Cytology. 2015;87: 137-144. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012;7:306-15. Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British journal of cancer. 2011;105:847-53. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial / mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British journal of cancer. 2011;105: 1338-41. Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, et al. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast cancer research : BCR. 2016; 18:44. Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, et al. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant BreastCancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev. 2016;25: 1037-42. Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, et al. Precision microfilters as an all in one system for multiplex analysis of circulating tumor cells. RSC Advances. 2016;6:6405-14. Adams DL, Alpaugh RK, Tsai S, Tang CM, Stefansson S. Multi -Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep. 2016;6:33488. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:3514-9. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10:6897-904. Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 2016; 16:744. Mu Z, Benali-Furet N, Uzan G, Znaty A, Ye Z, Paolillo C, et al. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. Int J Mol Sci. 2016;17.
Claims
WHAT IS CLAIMED IS:
1. A method of screening a subject having cancer for susceptibility to a beta-blocker, comprising assaying tumor associated macrophage (TAM) cells isolated from a subject having cancer for beta adrenergic receptor (BAR) expression, wherein when BAR expression is detected, the subject is deemed susceptible to a beta-blocker.
2. A method of predicting responsiveness of a subject having cancer to treatment with a beta-blocker, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is predicted to be responsive to treatment with a beta-blocker.
3. A method for selecting a treatment for a subject having cancer, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, administration of a therapeutically effective amount of a beta-blocker to the subject is selected as a treatment for the subject.
4. A method for identifying a subject having cancer suitable to receive a beta-blocker treatment, comprising assaying TAM cells isolated from a subject having cancer for BAR expression, wherein when BAR expression is detected, the subject is identified as a subject suitable to receive a beta-blocker treatment.
5. A method of treating a subject having cancer, comprising (a) assaying TAM cells isolated from a subject having cancer for BAR expression, and (b) administering a therapeutically effective amount of a beta-blocker to the subject when BAR expression is detected.
6. A method of treating a subject having cancer, comprising administering a therapeutically effective amount of a beta-blocker to a subject having cancer, wherein said beta-blocker is administered after BAR expression is detected in TAM cells isolated from the subject having cancer.
7. A method of obtaining data for evaluating beta-blocker treatment in a subject having cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from the subject having cancer.
8. A method of determining a likelihood that a subject having cancer will benefit from betablocker treatment, comprising measuring expression of BAR in TAM cells in a sampleobtained from the subject having cancer, wherein the subject having cancer is determined as having a relatively high likelihood of benefiting from the beta-blocker treatment when expression of BAR in TAM cells is relatively high, and wherein the subject having cancer is determined as having a relatively low likelihood of benefiting from the betablocker treatment when expression of BAR in TAM cells is relatively low.
9. A method of treating cancer, comprising measuring expression of BAR in TAM cells in a sample obtained from a subject having cancer, and administering a beta-blocker therapy to the subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the beta-blocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells.
10. A method of treating cancer, comprising administering a beta-blocker to a subject having cancer when the subject has relatively high expression of BAR in TAM cells, and not administering the beta-blocker to the subject having cancer when the subject has relatively low expression of BAR in TAM cells, in a sample obtained from the subject having cancer having been subjected to measurement of expression of BAR in TAM cells to determine the relative expression of BAR.
11. A method for predicting overall survival (OS) and / or progression free survival (PFS) of a subject having cancer, comprising determining the presence of TAM cells expressing BAR, wherein the presence of TAM cells expressing BAR predicts lower OS and / or PFS than a subject having the same cancer without the presence of TAM cells expressing BAR.
12. A method for predicting presence of metastatic spread and / or metastatic progression in a subject having cancer, comprising determining the presence of TAM cells expressing BAR in a biological sample from a subject having cancer, wherein the presence of TAM cells expressing BAR predicts presence of metastatic spread and / or metastatic progression in the subject.
13. The method of any one of claims 1-12, wherein the beta adrenergic receptor is beta-2 adrenergic receptor (B2AR).
14. The method of any one of claims 1-12, wherein the beta-blocker is one or more of propranolol, bucindolol, carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, metoprolol, nebivolol, esmolol, bButaxamine, ICI-118,551, SR 59230A, and nebivolol.
15. The method of any one of claims 1-10, wherein the beta-blocker is propranolol.
16. The method of any one of claims 1-12, wherein the TAM cells are Cancer Associated Macrophage-Like cells (CAMLs).
17. The method of any one of claims 1-12, wherein the cancer is a lung cancer, breast cancer, prostate cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, head and neck cancer, colorectal cancer, liver cancer, ovarian cancer, neuroblastoma, sarcoma, osteosarcoma, esophageal, brain & ONS, larynx, bronchus, oral cavity and pharynx, stomach, testis, thyroid, uterine cervix, uterine corpus cancer, or a blood cancer18. The method of any one of claims 1-12, wherein the subject having cancer is a breast cancer patient.
19. The method of any one of claims 5, 6, 9 and 10, further comprising administering a therapeutically effective amount of one or more additional anti-cancer agent to the subject.
20. The method of claim 19, wherein the additional anti-cancer agent is one or more agents selected from the group consisting of immunotherapeutic agents, chemotherapeutic agents, radiotherapeutic agents, CCR5 antagonists and CXCR4 antagonists.
21. The method of any one of claims 1-12, wherein BAR expression is assayed, measured, detected or determined via immunohistochemistry (IHC).
22. The method of claim 21, wherein IHC is performed by membrane staining, cytoplasmic staining, or a combination thereof.
23. The method of claim 21 or 22, wherein IHC is performed using an anti -BAR antibody24. The method of any one of claims 1-12, wherein TAM cells are isolated from blood obtained from the subject having cancer.
25. The method of any one of claims 1-12, wherein the subject having cancer is undergoing cancer treatment.
Citation Information
Patent Citations
New medical application of propranolol
CN113925852A
Methods for detecting and treating propranolol sensitive tumors
US20220049319A1
